Related references
Note: Only part of the references are listed.Next generation antibody drugs: pursuit of the 'high-hanging fruit'
Paul J. Carter et al.
NATURE REVIEWS DRUG DISCOVERY (2018)
Blinatumomab for minimal residual disease in adults with B-cell precursor acute lymphoblastic leukemia
Nicola Goekbuget et al.
BLOOD (2018)
Simultaneous multiple interaction T-cell engaging (SMITE) bispecific antibodies overcome bispecific T-cell engager (BiTE) resistance via CD28 co-stimulation
Colin E. Correnti et al.
LEUKEMIA (2018)
Development of MGD007, a gpA33 x CD3-Bispecific DART Protein for T-Cell Immunotherapy of Metastatic Colorectal Cancer
Paul A. Moore et al.
MOLECULAR CANCER THERAPEUTICS (2018)
T cell engaging bispecific antibody (T-BsAb): From technology to therapeutics
Z. Wu et al.
PHARMACOLOGY & THERAPEUTICS (2018)
Cancer immunotherapy using checkpoint blockade
Antoni Ribas et al.
SCIENCE (2018)
Comprehensive analysis of the clinical immuno-oncology landscape
J. Tang et al.
ANNALS OF ONCOLOGY (2018)
Resistance to anti-CD19/CD3 BiTE in acute lymphoblastic leukemia may be mediated by disrupted CD19 membrane trafficking
Friederike Braig et al.
BLOOD (2017)
Potent CD4+ T cell-associated antitumor memory responses induced by trifunctional bispecific antibodies in combination with immune checkpoint inhibition
Nina Deppisch et al.
ONCOTARGET (2017)
PD-1 Blockade Promotes Epitope Spreading in Anticancer CD8+ T Cell Responses by Preventing Fratricidal Death of Subdominant Clones To Relieve Immunodomination
Arash Memarnejadian et al.
JOURNAL OF IMMUNOLOGY (2017)
Frequency of regulatory T cells determines the outcome of the T-cell-engaging antibody blinatumomab in patients with B-precursor ALL
J. Duell et al.
LEUKEMIA (2017)
The making of bispecific antibodies
Ulrich Brinkmann et al.
MABS (2017)
Phenotypic and Functional Properties of Tumor-Infiltrating Regulatory T Cells
Gap Ryol Lee
MEDIATORS OF INFLAMMATION (2017)
Selective Blockade of the Ubiquitous Checkpoint Receptor CD47 Is Enabled by Dual-Targeting Bispecific Antibodies
Elie Dheilly et al.
MOLECULAR THERAPY (2017)
Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
J. D. Wolchok et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Blinatumomab versus Chemotherapy for Advanced Acute Lymphoblastic Leukemia
Hagop Kantarjian et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
An anti-glypican 3/CD3 bispecific T cell-redirecting antibody for treatment of solid tumors
Takahiro Ishiguro et al.
SCIENCE TRANSLATIONAL MEDICINE (2017)
Overcoming resistance to HER2-targeted therapy with a novel HER2/CD3 bispecific antibody
Andres Lopez-Albaitero et al.
ONCOIMMUNOLOGY (2017)
Combination Therapy with Bispecific Antibodies and PD-1 Blockade Enhances the Antitumor Potency of T Cells
Chien-Hsing Chang et al.
CANCER RESEARCH (2017)
Phase Ia and lb studies of the novel carcinoembryonic antigen (CEA) 1-cell bispecific (CEA CD3 TCB) antibody as a single agent and in combination with atezolizumab: Preliminary efficacy and safety in patients with metastatic colorectal cancer (mCRC).
Josep Tabernero et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Membrane-Proximal Epitope Facilitates Efficient T Cell Synapse Formation by Anti-FcRH5/CD3 and Is a Requirement for Myeloma Cell Killing
Ji Li et al.
CANCER CELL (2017)
Blockade of the PD-1/PD-L1 axis augments lysis of AML cells by the CD33/CD3 BiTE antibody construct AMG 330: reversing a T-cell-induced immune escape mechanism
C. Krupka et al.
LEUKEMIA (2016)
Expression of inhibitory receptors on intratumoral T cells modulates the activity of a T cell-bispecific antibody targeting folate receptor
Jens Schreiner et al.
ONCOIMMUNOLOGY (2016)
A review of blinatumomab, a novel immunotherapy
Matthew J. Newman et al.
JOURNAL OF ONCOLOGY PHARMACY PRACTICE (2016)
A phase I trial of the trifunctional anti Her2 x anti CD3 antibody ertumaxomab in patients with advanced solid tumors
N. Haense et al.
BMC CANCER (2016)
Checkpoint Antibodies but not T Cell-Recruiting Diabodies Effectively Synergize with TIL-Inducing γ-Irradiation
Michael Hettich et al.
CANCER RESEARCH (2016)
A Novel Carcinoembryonic Antigen T-Cell Bispecific Antibody (CEA TCB) for the Treatment of Solid Tumors
Marina Bacac et al.
CLINICAL CANCER RESEARCH (2016)
Bispecific T-Cell Engager (BiTE) Antibody Construct Blinatumomab for the Treatment of Patients With Relapsed/Refractory Non-Hodgkin Lymphoma: Final Results From a Phase I Study
Maria-Elisabeth Goebeler et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
The use of CrossMAb technology for the generation of bi- and multispecific antibodies
Christian Klein et al.
MABS (2016)
T-cell responses against CD19+ pediatric acute lymphoblastic leukemia mediated by bispecific T-cell engager (BiTE) are regulated contrarily by PD-L1 and CD80/CD86 on leukemic blasts
Judith Feucht et al.
ONCOTARGET (2016)
Evolving role of cetuximab in the treatment of colorectal cancer
Gunter Schuch
Cancer Management and Research (2016)
CEA/CD3-bispecific T cell-engaging (BiTE) antibody-mediated T lymphocyte cytotoxicity maximized by inhibition of both PD1 and PD-L1
Takuya Osada et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2015)
Immunotherapy in Tumors Activated T Cells as a New Treatment Modality
Sebastian Kobold et al.
DEUTSCHES ARZTEBLATT INTERNATIONAL (2015)
Increase of PD-L1 expressing B-precursor ALL cells in a patient resistant to the CD19/CD3-bispecific T cell engager antibody blinatumomab
Thomas Koehnke et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2015)
Therapeutic bispecific T-cell engager antibody targeting the intracellular oncoprotein WT1
Tao Dao et al.
NATURE BIOTECHNOLOGY (2015)
Nivolumab and Ipilimumab versus Ipilimumab in Untreated Melanoma
Michael A. Postow et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
T-cell ligands modulate the cytolytic activity of the CD33/CD3 BiTE antibody construct, AMG 330
G. S. Laszlo et al.
BLOOD CANCER JOURNAL (2015)
Antitumor Efficacy of a Bispecific Antibody That Targets HER2 and Activates T Cells
Teemu T. Junttila et al.
CANCER RESEARCH (2014)
Phase II Trial of the Anti-CD19 Bispecific T Cell-Engager Blinatumomab Shows Hematologic and Molecular Remissions in Patients With Relapsed or Refractory B-Precursor Acute Lymphoblastic Leukemia
Max S. Topp et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Genetic Basis for Clinical Response to CTLA-4 Blockade in Melanoma
Alexandra Snyder et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Anti-CTLA-4 therapy broadens the melanoma-reactive CD8+ T cell response
Pia Kvistborg et al.
SCIENCE TRANSLATIONAL MEDICINE (2014)
Antitumor Immunity: Easy as 1, 2, 3 with Monoclonal Bispecific Trifunctional Antibodies?
John Maher et al.
CANCER RESEARCH (2013)
SOX2-specific adaptive immunity and response to immunotherapy in non-small cell lung cancer
Kavita M. Dhodapkar et al.
ONCOIMMUNOLOGY (2013)
Cancer Immunotherapy Comes of Age
Suzanne L. Topalian et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Cancer immunotherapy comes of age
Ira Mellman et al.
NATURE (2011)
Biodistribution Mechanisms of Therapeutic Monoclonal Antibodies in Health and Disease
Mohammad Tabrizi et al.
AAPS JOURNAL (2010)
Catumaxomab Clinical development and future directions
Rolf Linke et al.
MABS (2010)
Bispecific T-Cell Engaging Antibodies for Cancer Therapy
Patrick A. Baeuerle et al.
CANCER RESEARCH (2009)
Examination of the contributions of size and avidity to the neutralization mechanisms of the anti-HIV antibodies b12 and 4E10
Joshua S. Klein et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2009)
The TeGenero Incident and the Duff Report Conclusions: A Series of Unfortunate Events or an Avoidable Event?
Christopher J. Horvath et al.
TOXICOLOGIC PATHOLOGY (2009)
Bi20 (FBTA05), a novel trifunctional bispecific antibody (anti-CD20 x anti-CD3), mediates efficient killing of B-cell lymphoma cells even with very low CD20 expression levels
Michael Stanglmaier et al.
INTERNATIONAL JOURNAL OF CANCER (2008)
CTLA-4 blockade enhances polyfunctional NY-ESO-1 specific T cell responses in metastatic melanoma patients with clinical benefit
Jianda Yuan et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2008)
Cancer immunoediting: from immunosurveillance to tumor escape
GP Dunn et al.
NATURE IMMUNOLOGY (2002)
Share Paper
